Antimetabolite (pyrimidine analog)

5 Drugs classified under this drug class

Antimetabolite (pyrimidine analog). Azacitidine 100 mg.
VIAL:Pwder for susp. for inj./inf. 1 X 100 mg
 First cycle:75 mg/m² SC or IV, daily for 7 days.
Subsequent Cycles: Repeat cycles every 4 weeks. Dose may be incr. to 100 mg/m² if no beneficial effect is seen after 2 cycles. It is recomm. that pts be treated for a min. of 4 to 6 cycles. See full prescript. info.
 For pts with the following FAB myelodysplastic syndr. subtypes: refractory anemia or refractory anemia with ringed sideroblasts ( if accompanied by neutropenia or thrombocytopenia or requiring transfusions),refractory anaemia with excess blasts, refractory anaemia with excess blasts in transformation, and chronic myelomonocytic leukaemia.
C/I:Hypersens. Adv. malignant hepatic tumors.

Antimetabolite (pyrimidine analog). Azacitidine 100 mg.
VIAL (Lyophilized pwdr. for suspens. for SC Inj./sol. for infus.): 1. 1^st tmt. cycle, for all pts. regardless of baseline hematology lab. values, is 75 mg/m² SC or IV, daily for 7 d. Premedicate pts. for nausea & vomit.
Obtain complete blood counts, hep. enzym., serum creatinine prior to the 1^st dose.
Subseq. Tmt. Cycles: Repeat cycles every 4 wks. The dose may be incr. to 100 mg/m² if no beneficial effect is seen after 2 tmt. cycles and if no toxicity other than nausea & vomit. has occurred. It is recomm. that pts. be treated for a min. of 4-6 cycles. However, complete or partial response may require addit. tmt. cycles. Tmt. may be continued as long as the pt. continues to benefit.
Tmt. of pts. with the following French-American-British (FAB) myelodysplastic syndr. subtypes: refract. anemia (RA) or refract. anemia with ringed sideroblasts (if accompan. by neutrop. or thrombocytop. or require. transfusions), refract. anemia with excess blasts (RAEB), refract. anemia with excess blasts in transformation (RAEB-T), and chron. myelomonocytic leukem. (CMMoL).
C/I: Hypersens. Pts. with advanced malig. hep. tumors.

Antimetabolite (pyrimidine analog). Capecitabine 500 mg.
TABS.: 120. Dosage should be ajust. individ.
Standard dose: The dosage is determ. based on a measure. called body surf. area.
The standard dose for adult. is 1250 mg per m2 of bdy. surf. area, taken twice a day (morn. & eve.). See lit.
Adjuv. colon canc.: for the adjuv. tmt. of pts. follow. surg. of stage III (Dukes stage C) colon canc.
Colorect. canc.: for the tmt. of pts. with advance. or metastat. colorect. canc.
Advanc.  gastr. canc.: for 1^st  line tmt. of advance. gastr. canc. in comb. with chemother.
Breast canc. comb. ther.: in comb. with docetaxel is indicated for the tmt. of pts. with metastat. breast canc. after fail.  of prior anthracycline-contain. chemother..
Breast canc. monother.: indic. for the tmt. of advance. or metastat. breast canc. after fail. of standard ther. includ. a taxane unless ther. with a taxane is clinical. contraindic.
C/I: History of sev. and unexpect. react.  to fluoropyrimidine ther.
Hypersens. to capecitabine or to any of the excipients, or fluorouracil.
In pts. with known dihydropyrimidine dehydrogenase (DPD) defic.
During pregn. / lact.
Pts. with severe leukopenia, neutropen., or thrombocytopen.
Pts. with sev. hep. impair.
Pts. with sev. renal impair. (CrCl <30 ml/min).
Tmt. with sorivudine or its chemic.  related analog., such as brivudine If contraindic. exist to any of the med.  products in the comb. regimen, that med. product should not be used.

Antimetabolite (pyrimidine analog). Gemcitabine (HCl) 200 mg.
VIALS: 1 x 200 mg. 1,000 mg/m².
See lit.
NSCLC, pancreat. cancer, bladder
cancer at invasive stage. In com. with
paclitaxel in unresect. local. recur. or metastat. Breast cancer who have
relapsed foll. adjuvant/ neoadjuvant
chemother. Prior chemother. should
have included an anthracycline unless
clin. contraindicat. in comb. With
carboplatin for tmt pts. with recur.
epithel. ovarian carcinoma who have
relapsed at least 6 mths aft. platinumbased
ther. Therapeut. activity:
Advanced or relapse.
epithel. ovarian cancer alone/in comb.
with other chemother. agents.
C/I: live attenuated vaccines, see lit.

Antimetabolite (pyrimidine analog). Azacitidine 100 mg.
VIAL: 1 x 100 mg. 1st cycle: 75 mg/m²
S.C. dly for 7 days. Premed. for naus./
vomit. See lit for subseq. cycles.
Myelodysplastic syndr. subtypes. See lit.
C/I: Hypersens. to azacitidine or mannitol, advanced malign. hepat. tumors.